Free tool
Stocks above their 200-day average
We cover 16 companies trading above their own 200-day average. The median market value in the group is $2.49B. Across the group, the median move over the past trading day is +0.04%. Price change over the past year runs from −33.3% to +274.8% across the middle 80 percent of the group, with a median of +25.0%.
Other lists in this group
Table
16 of 10,735 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| CHE | Chemed Corporation | $7.11B | Mid cap | +20.79% | Oct 27, 2026 |
| GETI-B.ST | Getinge AB (publ) | $7.01B | Mid cap | +20.89% | Oct 21, 2026 |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.05B | Mid cap | +133.47% | Oct 27, 2026 |
| SECT-B.ST | Sectra AB (publ) | $5.63B | Mid cap | −17.02% | Sep 4, 2026 |
| RCUS | Arcus Biosciences, Inc. | $3.92B | Mid cap | +191.29% | Oct 27, 2026 |
| NRIX | Nurix Therapeutics, Inc. | $2.77B | Mid cap | +179.69% | Oct 8, 2026 |
| WGS | GeneDx Holdings Corp. | $2.69B | Mid cap | −30.11% | Oct 27, 2026 |
| NEOG | Neogen Corporation | $2.54B | Mid cap | +103.83% | Oct 8, 2026 |
| ATRC | AtriCure, Inc. | $2.45B | Mid cap | +29.14% | Oct 27, 2026 |
| 3549.T | Kusuri No Aoki Holdings Co., Ltd. | $2.44B | Mid cap | +5.23% | Oct 1, 2026 |
| NEO | NeoGenomics, Inc. | $2.26B | Mid cap | +145.34% | Oct 27, 2026 |
| NBTX | Nanobiotix S.A. | $2.26B | Mid cap | +394.99% | Sep 29, 2026 |
| ALIF-B.ST | AddLife AB (publ) | $2.08B | Mid cap | −7.20% | Oct 21, 2026 |
| NANO.PA | Nanobiotix S.A. | $2.05B | Mid cap | +358.21% | Sep 29, 2026 |
| INTEG-B.ST | Integrum AB (publ) | $24.72M | Micro cap | −79.55% | Sep 3, 2026 |
| INM | InMed Pharmaceuticals Inc. | $7.64M | Micro cap | −36.44% | Sep 23, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.